The GBOT holds a virtual symposium to discuss the latest developments in the diagnosis and treatment of lung cancer
The Brazilian Thoracic Oncology Group (GBOT) held its 2020 Virtual Symposium on November 6th and 7th. For the first time, the event took place entirely online. “Due to the unusual format of the event, it was a challenge for the group and the board to develop a program that would be captivating, especially considering the amount of online lectures and symposia we have had over the last few months. However, I think that this format made the event more interactive because it enabled the participants to discuss topics and share their own experiences, rather than just listen to the lectures,” explains Dr. Ana Gelatti, the GBOT vice president. The aim of the symposium is to discuss the main developments in lung cancer diagnosis and treatment, as well as the latest evidences on tumor markers, new drugs and therapies. Around 400 pulmonologists, radio-oncologists, thoracic surgeons, clinical oncologists, and other specialists participated in the event. Dr. Gellati especially highlights the Sessions of Controversies regarding the management of patients with lung cancer. Osimertinib in adjuvant treatment, the relationship of two immunotherapies in first-line lung cancer treatment and the assessment of patient N2 and the best approach in their case were some of the topics discussed
A study to observe patients characteristics, tratments patterns and outcomes in patients with newly diagnosed breast cancer in Latin America – LATINA Breast (LACOG 0615/ MO39485)
Gustavo Werutsky, Cynthia Villareal-Garza, Henry Gomez, Juan Manuel Donaire, José Bines, Luis Fein, Mariano N. Carrizo, Facundo Zaffaroni, Paulo Ricardo Nunes Filho, Carlos H Barrios - 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020
Influence of physician’s lifestyle on the prescription of healthy habits to breast cancer patients (LACOG 1218)
Renata Cangussú, Eldsamira Mascarenhas, Taiane F Rebelatto, Paulo R Nunes, Rafaela G de Jesus, Facundo Zaffaroni and Gustavo Werutsky - 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020
Gustavo Werutsky, Daniela Dornelles Rosa, Carlos Barrios, Eduardo Cronemberger, Geraldo Queiroz, Jose Bines, Mahira Lopes Rosa, Rafaela Gomes, Ana P Heck, Laura Freitas, Arthur F da Silva, Matheus Rodrigues, Andre P Fay and Sergio Simon - 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020
The Brazilian Group for Thoracic Oncology (GBOT) is holding the “GBOT 2020 Online Symposium”, on November 6th and 7th, 2020 – an entirely online format for the first time.This well-established event is designed as an opportunity to discuss the main advances in the diagnosis and treatment of lung cancer, as well as the latest evidence on tumor markers and the development of new drugs and treatments. If you are a clinical oncologist, thoracic and oncology surgeon, radiotherapist, pulmonologist, pathologist, or other professional working in thoracic oncology, sign up and participate! Sign up here: http://www.simposionacionalgbot.com.br/
A study conducted by the Genitourinary Cancer Group has been published in an important American journal
In August, the journal Clinical Genitourinary Cancer published the study “First-line treatment of metastatic renal cell carcinoma in the immuno-oncology era: systematic review and network meta-analysis”, authored by a group of researchers from the LACOG Genitourinary Group. According to Dr. Fernando Sabino, a clinical oncologist at the Oncology and Hematology Center at Santa Lúcia Hospital and the Hospital of the University of Brasilia, the aim of the study was to compare and classify the different regimens available for first-line treatment of metastatic kidney cancer. This systematic review and meta-analysis has provided some important information on which treatments are most suitable for patients with this type of tumor, as there are, to date, no studies that compare the latest approaches, e.g. combining immunological agents of different classes or combining these agents with targeted molecular therapy. “The established outcomes we looked at were overall survival, progression-free survival and response rates. The study concluded that the treatments using immunotherapy are superior to the standard treatment with Sunitinib, and that there is no one immunotherapy based treatment that is significantly superior to any other.” In Dr. Sabino’s opinion, this study has had a significant impact on patients in Latin America, because five first-line line systemic therapeutic options
The same way it happens in developed countries, non-small cell lung cancer (NSCLC) is generally diagnosed in its advanced stages and has poor survival rates in Brazil. Overall, approximately 70% of patients present with locally advanced or metastatic disease (stages III and IV, respectively) at diagnosis.1 In order to collect data on clinical characteristics, treatment patterns and outcomes of patients with stage III NSCLC in Brazil, Dr. Vladmir Cláudio Cordeiro de Lima started the observational study Retrospective epidemiological study of Locally Advanced Non-Small Cell Lung Cancer (LACOG 0118 – RELANCE). He has worked as the principal investigator of the study ever since. Dr. Cordeiro de Lima is a clinical oncologist at the Department of Clinical Oncology at the AC Camargo Cancer Center. He also works as a permanent advisor of the Postgraduate Course in Sciences focused on the Oncology area at the Antônio Prudente Foundation, and as an investigator at the Translational Immuno-oncology Laboratory (CIPE) at the Antônio Prudente Foundation. The study aims to describe the outcomes of 400 patients with locally advanced NSCLC (stage III). The study is supported by LACOG and, according to Dr. Cordeiro de Lima, this support is extremely important because cooperative groups help to bring together and
The results of the PALLAS study, which evaluated the addition of Palbociclib to adjuvant endocrine therapy in breast cancer, were presented at the ESMOVirtual Congress 2020 on September 20, 2020.The PALLAS study was conducted by the Austrian Breast and Colorectal Cancer Study Group (ABCSG), Austria and the ALLIANCE Foundation Trials group - United States. LACOG participated in the study as part of a collaborative group working in Latin America along with Mexican research centers that made a significant contribution to the study.
GEICAM started this initiative in 2008 with the purpose of presenting an in-depth review of the most relevant milestones presented at congresses and international publications annually. At this annual multidisciplinary meeting, attended by all professional involved with breast cancer, a comprehensive review of the advances made in research, diagnosis and treatment in connection with this disease has been carried out. The main goal of this event is to become a reference for everyone interested in finding out more about the advances made in terms of breast cancer in an independent, comprehensive and critical fashion. Sign up at: https://www.ragmageicam.org/ and participate!
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)
Members of LACOG Breast cancer group have recently published the article “The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)” AMAZONA III/ GBECAM 0115 is a prospective cohort study that evaluated Brazilian patients with newly diagnosed breast cancer from 2016 to 2018. This manuscript depicts a wide and detailed scenario of sociodemographic characteristics of 2,950 breast cancer patients at diagnosis. The patients were from 23 sites in Brazil. The results of the study show that patients with public health coverage were diagnosed with symptomatic disease, at later stages and with more aggressive subtypes of breast cancer when compared to patients with private health coverage. This study brings to light important information that allows us to not only have a better understanding of tumor and patients’ characteristics but also, help to identify gaps within healthcare systems in Brazil. With such knowledge, it’s possible to develop strategies to improve screening and educational programs in the country, especially in the public setting.